Abstract
Although systemic steroids or orbital radiotherapy are effective in limiting the inflammatory response in thyroid eye disease (TED), there are reports of over 70% of treated patients requiring subsequent rehabilitative surgery: either orbital decompression or strabismus correction. This study investigated whether combined immunosuppression with primary orbital radiotherapy together with azathioprine and low-dose prednisolone, applied early in the active disease state, was more effective in treating TED. Forty consecutive patients with active TED were recruited. Orbital MRI (STIR sequence) was used to assess disease activity. Median duration of symptoms was 1.0 year. Subjects were treated with bilateral orbital radiotherapy (20 Gy in 10 fractions) and oral prednisolone and azathioprine. Pre- and post-treatment activity was measured clinically, including uniocular field of fixation, Mourits score and total eye score, until TED became inactive off all treatment. Before treatment, 15 subjects had signs of dysthyroid optic neuropathy, 35 had significant motility restriction and 38 had marked soft tissue signs. On average TED became inactive after 1.2 years (SD 0.7) of immunosuppression, and treatment was well tolerated. One patient required subsequent cosmetic orbital decompression, 6 had successful strabismus surgery and 13 required minor cosmetic lid surgery. Compared with previously reported treatment regimes we think that combined orbital radiotherapy and medical immunosuppression is far more effective than either treatment alone in the management of active TED, and led to fewer side effects of high-dose steroids. In particular there was more than a four-fold reduction in the requirement for orbital decompression and strabismus surgery.
Similar content being viewed by others
Article PDF
References
Fells P . Systemic management of dysthyroid ophthalmopathy. Eye 1988;2:198–200.
Char DH . Thyroid eye disease. Br J Ophthalmol 1996;80:922–6.
Shorr N, Seiff SR . The four stages of surgical rehabilitation of the patient with dysthyroid ophthalmopathy. Ophthalmology 1986;93:476–83.
Hales IB, Rundle FF . Ocular changes in Graves' disease: a long-term follow-up study. Q J Med 1960;29:113–26.
Shorr N, Neuhaus RW, Baylis HI . Ocular motility problems after orbital decompression for dysthyroid ophthalmolopathy. Ophthalmology 1982;89:323–8.
McCord CD Jr. Current trends in orbital decompression. Ophthalmology 1985;92:21–33.
Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al. Prednisolone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989;321:1353–9.
Burrow GN, Mitchell MS, Howard RO, Morrow LB . Immunosuppressive therapy for the eye changes of Graves' disease. J Clin Endocrinol Metab 1970;31:307–11.
Yamamoto K, Saito K, Takai T, Yoshida S . Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement. Endocrinol Japon 1982;29:495–501.
Atabay C, Schrooyen M, Zhang ZG, Salvi M, Glinoer D, Wall JR . Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid associated ophthalmopathy. J Endocrinol Invest 1993;16:669–74.
Brennan MW, Leone CR Jr, Janaki L . Radiation therapy for Graves' disease. Am J Ophthalmol 1983;96:195–9.
Olivotto IA, Ludgate CM, Allen LH, Rootman J . Supervoltage radiotherapy for Graves' ophthalmolopathy: CCABC technique and results. Int J Radiat Oncol Biol Phys 1985;11:2085–90.
Palmer D, Greenberg P, Cornell P, Parker RG . Radiation therapy for Graves' ophthalmolopathy: a retrospective study. Int J Radiat Oncol Biol Phys 1987;13:1815–20.
Petersen IA, Kriss JP, McDougall IR, Donaldson SS . Prognostic factors in the radiotherapy of Graves' ophthalmolopathy. Int J Radiat Oncol Biol Phys 1990;19:259–64.
Hurbli T, Char DC, Harris J, Weaver K, Greenspan F, Sheline G . Radiation therapy for thyroid eye disease. Am J Ophthalmol 1985;99:633–7.
Donaldson SS, Bagshaw MA, Kriss JP . Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 1973;37:276–85.
Teng CS, Crombie AL, Hall R, Ross WM . An evaluation of supervoltage orbital irradiation for Graves' ophthalmopathy. Clin Endocrinol 1980;13:545–51.
Kazim M, Trokel S, Moore S . Treatment of acute Graves' orbitopathy. Ophthalmology 1991;98:1443–8.
Prummel MF, Mourits MP, Blank L, Berhout A, Koornneef L, Wiersinga WM . Randomised double-blind trial of prednisolone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993;342:949–54.
Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983;56:1139–44.
Rundle FF, Wilson CW . Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clin Sci 1944;5:177–94.
Bahn RS, Heufelder AE . Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993;329:1468–75.
Wiersinga WM . Immunosuppression in endocrine ophthalmopathy: why and when? In: Kahaly G, editor. Endocrine ophthalmopathy. Basel: Karger, 1993: 120–30.
Steel DHW, Hoh HB, Potts MJ, Harrad RA . Uniocular fields of fixation in thyroid eye disease. Eye 1995;9:348–51.
Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Gaag RVD . Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639–44.
Werner SC . Classification of the eye changes of Graves' disease. J Clin Endocrinol Metab 1969;29:782–4.
Werner SC . Modifications of the classification of the eye changes of Graves' disease. Am J Ophthalmol 1977;83:725–7.
Hoh HB, Laitt RD, Wakeley C, Kabala J, Goddard P, Potts MJ, et al. The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease. Eye 1994;8:506–10.
In: ABPI Data Sheet Compendium. London: Data-pharm Publications, 1995:1929–32.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Claridge, K., Ghabrial, R., Davis, G. et al. Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye 11, 717–722 (1997). https://doi.org/10.1038/eye.1997.183
Issue Date:
DOI: https://doi.org/10.1038/eye.1997.183
Keywords
This article is cited by
-
Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial
Trials (2008)
-
Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid eye disease
Eye (2001)
-
Thyroid eye disease
Current Treatment Options in Neurology (2000)
-
An unusual presentation of Graves' disease
Eye (1999)
-
An ounce of prevention is worth a pound of cure?
Eye (1997)